Drugs / URB597
URB597
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00916201 | Jan 2025 | schizophrenia | Central Institute of Mental Health, Mannheim | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | URB597 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00916201 ↗ |
| Known as | KDS-4103 | ChEMBL registry synonym — accepted as the source's own label CHEMBL184238 ↗ |
| Known as | ORG-231295 | ChEMBL registry synonym — accepted as the source's own label CHEMBL184238 ↗ |
| Action | Inhibit | “URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.” NCT00916201 ↗ |
| Modality | Small molecule | — CHEMBL184238 ↗ |
| Route | Oral | “10 mg / d for 5 days, orally” NCT00916201 ↗ |